Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial.

Viruses · 2025 · PMC12299281 · PMID 40733599

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

approached significancep = 0.073so close (0.05 < p ≤ 0.1)

The respiratory function test at 30 days in the moderate pneumonia group tended to be better than that in the AM group and approached significance ( p = 0.073).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.